For the year ending 2025-12-31, SPRO had -$12,624K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 8,572 |
| Depreciation and amortization | 0 |
| Non-cash lease cost | 1,048 |
| Impairment of assets | 587 |
| Share-based compensation | 4,325 |
| Collaboration receivable, current and non-current - related party | -24,032 |
| Other receivables | -3,057 |
| Prepaid expenses and other current assets | -277 |
| Other assets | 0 |
| Accounts payable | -6,613 |
| Accrued expenses and other current liabilities | -12,146 |
| Deferred revenue | -12,587 |
| Deferred revenue - related party | -22,074 |
| Other long-term liabilities | 91 |
| Operating lease liabilities | -1,402 |
| Income taxes payable | 209 |
| Net cash used in operating activities | -12,624 |
| Net decrease in cash and cash equivalents | -12,624 |
| Cash and cash equivalents at beginning of period | 52,889 |
| Cash and cash equivalents at end of period | 40,265 |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)